Explore New Strategies for Treating Retinal Vascular Disease at SMi’s 2nd annual Ophthalmic Drugs 2018

SMi Group are delighted to welcome the expertise from a senior panel of big pharma and ophthalmic organisations, as well as regulatory bodies, at the 2nd annual Ophthalmic Drugs 2018 conference, taking place in November in the City of London, UK.

Day 1 - Opening Address: New Strategies for Treating Retinal Vascular Diseases:

Discover advancements in the treatment of ocular diseases as Professor Alan Stitt, Dean of Innovation and Impact, Queen's University Belfast presents an overview of pathogenesis of ischaemic retinopathies, a disease that affects the immature retinal vascular system, as well as the cellular and molecular mechanisms of the disease. Check out the full presentation details online, as Alan looks ahead to new treatment pathways and improved use of preclinical evidence in the clinical setting to aid translation.

Professor Stitt’s research is in the inter-related areas of diabetic retinopathy, retinal angiogenesis and microvascular biology. His work has uncovered some key pathogenic pathways involved in neuroglial and microvascular dysfunction in the diabetic retina and this has led to the development and testing of several compounds that have progressed to clinical trials.

Alan holds a Royal Society Wolfson Merit award and is the Editor of Current Eye Research, an Associate Editor for Diabetologia and currently sits on several other editorial board and panels.

Have you seen the full speaker line-up? Companies include Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more!

Chair’s for 2018:

- Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals
- Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen

Key Speakers:

- Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
- Caroline Barelle, CEO, Elasmogen
- Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
- Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
- Aniz Girach, Chief Medical Officer, Nightstar Therapeutics
- Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
- David Silverman, Clinical Director, Ophthalmology, Roche

For those looking to attend, there is currently a £300 early-bird saving, ending June 29th.

Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the attendee list from last year at: www.ophthalmicdrugs.com/opr

SMi presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/opr

Sponsors: Experimentica | Nemera

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Westminster Bridge Road
1

This release was published on openPR.